Losartan in postmenopausal women with essential arterial hypertension

Aim. To study losartan effectiveness and safety in postmenopausal women with essential arterial hypertension (EAH), and with or without hormone replacement therapy (HRT). Material and methods. In total, 58 postmenopausal women with EAH were followed up for 6 months after being administered antihyper...
Ausführliche Beschreibung

Gespeichert in:

Autor*in:	O. N. Tkacheva [verfasserIn] A. V. Barabashkina [verfasserIn] I. M. Novikova [verfasserIn] N. V. Sharashkina [verfasserIn]

Format:	E-Artikel
Sprache:	Russisch

Erschienen:	2010

Schlagwörter:	артериальная гипертония постменопауза лозартан

Übergeordnetes Werk:	In: Кардиоваскулярная терапия и профилактика - «SILICEA-POLIGRAF» LLC, 2019, 9(2010), 6, Seite 25-31
Übergeordnetes Werk:	volume:9 ; year:2010 ; number:6 ; pages:25-31

Links:	Link aufrufen Link aufrufen Journal toc Journal toc

Katalog-ID:	DOAJ084683821

Internformat


LEADER	01000caa a22002652 4500
001	DOAJ084683821
003	DE-627
005	20230502081526.0
007	cr uuu---uuuuu
008	230311s2010 xx \|\|\|\|\|o 00\| \|\|rus c
035			\|a (DE-627)DOAJ084683821
035			\|a (DE-599)DOAJ7583c3ea53714e26875299df90356076
040			\|a DE-627 \|b ger \|c DE-627 \|e rakwb
041			\|a rus
050		0	\|a RC666-701
100	0		\|a O. N. Tkacheva \|e verfasserin \|4 aut
245	1	0	\|a Losartan in postmenopausal women with essential arterial hypertension
264		1	\|c 2010
336			\|a Text \|b txt \|2 rdacontent
337			\|a Computermedien \|b c \|2 rdamedia
338			\|a Online-Ressource \|b cr \|2 rdacarrier
520			\|a Aim. To study losartan effectiveness and safety in postmenopausal women with essential arterial hypertension (EAH), and with or without hormone replacement therapy (HRT). Material and methods. In total, 58 postmenopausal women with EAH were followed up for 6 months after being administered antihypertensive therapy (AHT) with losartan, due to inadequate blood pressure (BP) control. Group I (n=30) did not receive HRT, while Group II (n=28) was administered HRT. Losartan effects on BP dynamics, endothelium-dependent vasodilatation (EDVD), intima-media thickness (IMT) of carotid arteries (CA), lipid and carbohydrate metabolism were assessed, as well as losartan tolerability. Results. Losartan therapy resulted in target BP level achievement in both groups. At the study end, EDVD increase was statistically significant in Group I (р<0,05) and highly significant in Group II (р<0,001). In both groups, a tendency towards CA IMT reduction was observed. In all participants, a positive dynamics of lipid profile was observed, but it reached statistical significance only for low-density lipoprotein cholesterol in Group II. After 6 months, insulin sensitivity was normalized in all patients. The tolerability of losartan was good throughout the study period. Conclusion. In postmenopausal women with AH, adding losartan to the AHT scheme demonstrated good antihypertensive effectiveness, insulin sensitivity normalization, endothelial function and lipid profile improvement. Among women receiving AHT and HRT, antihypertensive effect, as well as beneficial effects on endothelial function and lipid profile, was greater than in women receiving AHT only.
650		4	\|a артериальная гипертония
650		4	\|a постменопауза
650		4	\|a лозартан
653		0	\|a Diseases of the circulatory (Cardiovascular) system
700	0		\|a A. V. Barabashkina \|e verfasserin \|4 aut
700	0		\|a I. M. Novikova \|e verfasserin \|4 aut
700	0		\|a N. V. Sharashkina \|e verfasserin \|4 aut
773	0	8	\|i In \|t Кардиоваскулярная терапия и профилактика \|d «SILICEA-POLIGRAF» LLC, 2019 \|g 9(2010), 6, Seite 25-31 \|w (DE-627)1725534363 \|x 26190125 \|7 nnns
773	1	8	\|g volume:9 \|g year:2010 \|g number:6 \|g pages:25-31
856	4	0	\|u https://doaj.org/article/7583c3ea53714e26875299df90356076 \|z kostenfrei
856	4	0	\|u https://cardiovascular.elpub.ru/jour/article/view/2141 \|z kostenfrei
856	4	2	\|u https://doaj.org/toc/1728-8800 \|y Journal toc \|z kostenfrei
856	4	2	\|u https://doaj.org/toc/2619-0125 \|y Journal toc \|z kostenfrei
912			\|a GBV_USEFLAG_A
912			\|a SYSFLAG_A
912			\|a GBV_DOAJ
912			\|a SSG-OLC-PHA
912			\|a GBV_ILN_20
912			\|a GBV_ILN_22
912			\|a GBV_ILN_23
912			\|a GBV_ILN_24
912			\|a GBV_ILN_31
912			\|a GBV_ILN_39
912			\|a GBV_ILN_40
912			\|a GBV_ILN_60
912			\|a GBV_ILN_62
912			\|a GBV_ILN_63
912			\|a GBV_ILN_65
912			\|a GBV_ILN_69
912			\|a GBV_ILN_73
912			\|a GBV_ILN_74
912			\|a GBV_ILN_95
912			\|a GBV_ILN_105
912			\|a GBV_ILN_110
912			\|a GBV_ILN_151
912			\|a GBV_ILN_161
912			\|a GBV_ILN_170
912			\|a GBV_ILN_206
912			\|a GBV_ILN_213
912			\|a GBV_ILN_230
912			\|a GBV_ILN_285
912			\|a GBV_ILN_293
912			\|a GBV_ILN_602
912			\|a GBV_ILN_2014
912			\|a GBV_ILN_4012
912			\|a GBV_ILN_4037
912			\|a GBV_ILN_4112
912			\|a GBV_ILN_4125
912			\|a GBV_ILN_4126
912			\|a GBV_ILN_4249
912			\|a GBV_ILN_4305
912			\|a GBV_ILN_4306
912			\|a GBV_ILN_4307
912			\|a GBV_ILN_4313
912			\|a GBV_ILN_4322
912			\|a GBV_ILN_4323
912			\|a GBV_ILN_4324
912			\|a GBV_ILN_4325
912			\|a GBV_ILN_4338
912			\|a GBV_ILN_4367
912			\|a GBV_ILN_4700
951			\|a AR
952			\|d 9 \|j 2010 \|e 6 \|h 25-31

Indexfelder

author_variant	o n t ont a v b avb i m n imn n v s nvs
matchkey_str	article:26190125:2010----::oatnnoteoasloewtesnilr
hierarchy_sort_str	2010
callnumber-subject-code	RC
publishDate	2010
allfields	(DE-627)DOAJ084683821 (DE-599)DOAJ7583c3ea53714e26875299df90356076 DE-627 ger DE-627 rakwb rus RC666-701 O. N. Tkacheva verfasserin aut Losartan in postmenopausal women with essential arterial hypertension 2010 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Aim. To study losartan effectiveness and safety in postmenopausal women with essential arterial hypertension (EAH), and with or without hormone replacement therapy (HRT). Material and methods. In total, 58 postmenopausal women with EAH were followed up for 6 months after being administered antihypertensive therapy (AHT) with losartan, due to inadequate blood pressure (BP) control. Group I (n=30) did not receive HRT, while Group II (n=28) was administered HRT. Losartan effects on BP dynamics, endothelium-dependent vasodilatation (EDVD), intima-media thickness (IMT) of carotid arteries (CA), lipid and carbohydrate metabolism were assessed, as well as losartan tolerability. Results. Losartan therapy resulted in target BP level achievement in both groups. At the study end, EDVD increase was statistically significant in Group I (р<0,05) and highly significant in Group II (р<0,001). In both groups, a tendency towards CA IMT reduction was observed. In all participants, a positive dynamics of lipid profile was observed, but it reached statistical significance only for low-density lipoprotein cholesterol in Group II. After 6 months, insulin sensitivity was normalized in all patients. The tolerability of losartan was good throughout the study period. Conclusion. In postmenopausal women with AH, adding losartan to the AHT scheme demonstrated good antihypertensive effectiveness, insulin sensitivity normalization, endothelial function and lipid profile improvement. Among women receiving AHT and HRT, antihypertensive effect, as well as beneficial effects on endothelial function and lipid profile, was greater than in women receiving AHT only. артериальная гипертония постменопауза лозартан Diseases of the circulatory (Cardiovascular) system A. V. Barabashkina verfasserin aut I. M. Novikova verfasserin aut N. V. Sharashkina verfasserin aut In Кардиоваскулярная терапия и профилактика «SILICEA-POLIGRAF» LLC, 2019 9(2010), 6, Seite 25-31 (DE-627)1725534363 26190125 nnns volume:9 year:2010 number:6 pages:25-31 https://doaj.org/article/7583c3ea53714e26875299df90356076 kostenfrei https://cardiovascular.elpub.ru/jour/article/view/2141 kostenfrei https://doaj.org/toc/1728-8800 Journal toc kostenfrei https://doaj.org/toc/2619-0125 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ SSG-OLC-PHA GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 9 2010 6 25-31
spelling	(DE-627)DOAJ084683821 (DE-599)DOAJ7583c3ea53714e26875299df90356076 DE-627 ger DE-627 rakwb rus RC666-701 O. N. Tkacheva verfasserin aut Losartan in postmenopausal women with essential arterial hypertension 2010 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Aim. To study losartan effectiveness and safety in postmenopausal women with essential arterial hypertension (EAH), and with or without hormone replacement therapy (HRT). Material and methods. In total, 58 postmenopausal women with EAH were followed up for 6 months after being administered antihypertensive therapy (AHT) with losartan, due to inadequate blood pressure (BP) control. Group I (n=30) did not receive HRT, while Group II (n=28) was administered HRT. Losartan effects on BP dynamics, endothelium-dependent vasodilatation (EDVD), intima-media thickness (IMT) of carotid arteries (CA), lipid and carbohydrate metabolism were assessed, as well as losartan tolerability. Results. Losartan therapy resulted in target BP level achievement in both groups. At the study end, EDVD increase was statistically significant in Group I (р<0,05) and highly significant in Group II (р<0,001). In both groups, a tendency towards CA IMT reduction was observed. In all participants, a positive dynamics of lipid profile was observed, but it reached statistical significance only for low-density lipoprotein cholesterol in Group II. After 6 months, insulin sensitivity was normalized in all patients. The tolerability of losartan was good throughout the study period. Conclusion. In postmenopausal women with AH, adding losartan to the AHT scheme demonstrated good antihypertensive effectiveness, insulin sensitivity normalization, endothelial function and lipid profile improvement. Among women receiving AHT and HRT, antihypertensive effect, as well as beneficial effects on endothelial function and lipid profile, was greater than in women receiving AHT only. артериальная гипертония постменопауза лозартан Diseases of the circulatory (Cardiovascular) system A. V. Barabashkina verfasserin aut I. M. Novikova verfasserin aut N. V. Sharashkina verfasserin aut In Кардиоваскулярная терапия и профилактика «SILICEA-POLIGRAF» LLC, 2019 9(2010), 6, Seite 25-31 (DE-627)1725534363 26190125 nnns volume:9 year:2010 number:6 pages:25-31 https://doaj.org/article/7583c3ea53714e26875299df90356076 kostenfrei https://cardiovascular.elpub.ru/jour/article/view/2141 kostenfrei https://doaj.org/toc/1728-8800 Journal toc kostenfrei https://doaj.org/toc/2619-0125 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ SSG-OLC-PHA GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 9 2010 6 25-31
allfields_unstemmed	(DE-627)DOAJ084683821 (DE-599)DOAJ7583c3ea53714e26875299df90356076 DE-627 ger DE-627 rakwb rus RC666-701 O. N. Tkacheva verfasserin aut Losartan in postmenopausal women with essential arterial hypertension 2010 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Aim. To study losartan effectiveness and safety in postmenopausal women with essential arterial hypertension (EAH), and with or without hormone replacement therapy (HRT). Material and methods. In total, 58 postmenopausal women with EAH were followed up for 6 months after being administered antihypertensive therapy (AHT) with losartan, due to inadequate blood pressure (BP) control. Group I (n=30) did not receive HRT, while Group II (n=28) was administered HRT. Losartan effects on BP dynamics, endothelium-dependent vasodilatation (EDVD), intima-media thickness (IMT) of carotid arteries (CA), lipid and carbohydrate metabolism were assessed, as well as losartan tolerability. Results. Losartan therapy resulted in target BP level achievement in both groups. At the study end, EDVD increase was statistically significant in Group I (р<0,05) and highly significant in Group II (р<0,001). In both groups, a tendency towards CA IMT reduction was observed. In all participants, a positive dynamics of lipid profile was observed, but it reached statistical significance only for low-density lipoprotein cholesterol in Group II. After 6 months, insulin sensitivity was normalized in all patients. The tolerability of losartan was good throughout the study period. Conclusion. In postmenopausal women with AH, adding losartan to the AHT scheme demonstrated good antihypertensive effectiveness, insulin sensitivity normalization, endothelial function and lipid profile improvement. Among women receiving AHT and HRT, antihypertensive effect, as well as beneficial effects on endothelial function and lipid profile, was greater than in women receiving AHT only. артериальная гипертония постменопауза лозартан Diseases of the circulatory (Cardiovascular) system A. V. Barabashkina verfasserin aut I. M. Novikova verfasserin aut N. V. Sharashkina verfasserin aut In Кардиоваскулярная терапия и профилактика «SILICEA-POLIGRAF» LLC, 2019 9(2010), 6, Seite 25-31 (DE-627)1725534363 26190125 nnns volume:9 year:2010 number:6 pages:25-31 https://doaj.org/article/7583c3ea53714e26875299df90356076 kostenfrei https://cardiovascular.elpub.ru/jour/article/view/2141 kostenfrei https://doaj.org/toc/1728-8800 Journal toc kostenfrei https://doaj.org/toc/2619-0125 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ SSG-OLC-PHA GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 9 2010 6 25-31
allfieldsGer	(DE-627)DOAJ084683821 (DE-599)DOAJ7583c3ea53714e26875299df90356076 DE-627 ger DE-627 rakwb rus RC666-701 O. N. Tkacheva verfasserin aut Losartan in postmenopausal women with essential arterial hypertension 2010 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Aim. To study losartan effectiveness and safety in postmenopausal women with essential arterial hypertension (EAH), and with or without hormone replacement therapy (HRT). Material and methods. In total, 58 postmenopausal women with EAH were followed up for 6 months after being administered antihypertensive therapy (AHT) with losartan, due to inadequate blood pressure (BP) control. Group I (n=30) did not receive HRT, while Group II (n=28) was administered HRT. Losartan effects on BP dynamics, endothelium-dependent vasodilatation (EDVD), intima-media thickness (IMT) of carotid arteries (CA), lipid and carbohydrate metabolism were assessed, as well as losartan tolerability. Results. Losartan therapy resulted in target BP level achievement in both groups. At the study end, EDVD increase was statistically significant in Group I (р<0,05) and highly significant in Group II (р<0,001). In both groups, a tendency towards CA IMT reduction was observed. In all participants, a positive dynamics of lipid profile was observed, but it reached statistical significance only for low-density lipoprotein cholesterol in Group II. After 6 months, insulin sensitivity was normalized in all patients. The tolerability of losartan was good throughout the study period. Conclusion. In postmenopausal women with AH, adding losartan to the AHT scheme demonstrated good antihypertensive effectiveness, insulin sensitivity normalization, endothelial function and lipid profile improvement. Among women receiving AHT and HRT, antihypertensive effect, as well as beneficial effects on endothelial function and lipid profile, was greater than in women receiving AHT only. артериальная гипертония постменопауза лозартан Diseases of the circulatory (Cardiovascular) system A. V. Barabashkina verfasserin aut I. M. Novikova verfasserin aut N. V. Sharashkina verfasserin aut In Кардиоваскулярная терапия и профилактика «SILICEA-POLIGRAF» LLC, 2019 9(2010), 6, Seite 25-31 (DE-627)1725534363 26190125 nnns volume:9 year:2010 number:6 pages:25-31 https://doaj.org/article/7583c3ea53714e26875299df90356076 kostenfrei https://cardiovascular.elpub.ru/jour/article/view/2141 kostenfrei https://doaj.org/toc/1728-8800 Journal toc kostenfrei https://doaj.org/toc/2619-0125 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ SSG-OLC-PHA GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 9 2010 6 25-31
allfieldsSound	(DE-627)DOAJ084683821 (DE-599)DOAJ7583c3ea53714e26875299df90356076 DE-627 ger DE-627 rakwb rus RC666-701 O. N. Tkacheva verfasserin aut Losartan in postmenopausal women with essential arterial hypertension 2010 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Aim. To study losartan effectiveness and safety in postmenopausal women with essential arterial hypertension (EAH), and with or without hormone replacement therapy (HRT). Material and methods. In total, 58 postmenopausal women with EAH were followed up for 6 months after being administered antihypertensive therapy (AHT) with losartan, due to inadequate blood pressure (BP) control. Group I (n=30) did not receive HRT, while Group II (n=28) was administered HRT. Losartan effects on BP dynamics, endothelium-dependent vasodilatation (EDVD), intima-media thickness (IMT) of carotid arteries (CA), lipid and carbohydrate metabolism were assessed, as well as losartan tolerability. Results. Losartan therapy resulted in target BP level achievement in both groups. At the study end, EDVD increase was statistically significant in Group I (р<0,05) and highly significant in Group II (р<0,001). In both groups, a tendency towards CA IMT reduction was observed. In all participants, a positive dynamics of lipid profile was observed, but it reached statistical significance only for low-density lipoprotein cholesterol in Group II. After 6 months, insulin sensitivity was normalized in all patients. The tolerability of losartan was good throughout the study period. Conclusion. In postmenopausal women with AH, adding losartan to the AHT scheme demonstrated good antihypertensive effectiveness, insulin sensitivity normalization, endothelial function and lipid profile improvement. Among women receiving AHT and HRT, antihypertensive effect, as well as beneficial effects on endothelial function and lipid profile, was greater than in women receiving AHT only. артериальная гипертония постменопауза лозартан Diseases of the circulatory (Cardiovascular) system A. V. Barabashkina verfasserin aut I. M. Novikova verfasserin aut N. V. Sharashkina verfasserin aut In Кардиоваскулярная терапия и профилактика «SILICEA-POLIGRAF» LLC, 2019 9(2010), 6, Seite 25-31 (DE-627)1725534363 26190125 nnns volume:9 year:2010 number:6 pages:25-31 https://doaj.org/article/7583c3ea53714e26875299df90356076 kostenfrei https://cardiovascular.elpub.ru/jour/article/view/2141 kostenfrei https://doaj.org/toc/1728-8800 Journal toc kostenfrei https://doaj.org/toc/2619-0125 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ SSG-OLC-PHA GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 9 2010 6 25-31
language	Russian
source	In Кардиоваскулярная терапия и профилактика 9(2010), 6, Seite 25-31 volume:9 year:2010 number:6 pages:25-31
sourceStr	In Кардиоваскулярная терапия и профилактика 9(2010), 6, Seite 25-31 volume:9 year:2010 number:6 pages:25-31
format_phy_str_mv	Article
institution	findex.gbv.de
topic_facet	артериальная гипертония постменопауза лозартан Diseases of the circulatory (Cardiovascular) system
isfreeaccess_bool	true
container_title	Кардиоваскулярная терапия и профилактика
authorswithroles_txt_mv	O. N. Tkacheva @@aut@@ A. V. Barabashkina @@aut@@ I. M. Novikova @@aut@@ N. V. Sharashkina @@aut@@
publishDateDaySort_date	2010-01-01T00:00:00Z
hierarchy_top_id	1725534363
id	DOAJ084683821
language_de	russisch
fullrecord	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ084683821</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230502081526.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230311s2010 xx \|\|\|\|\|o 00\| \|\|rus c</controlfield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ084683821</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJ7583c3ea53714e26875299df90356076</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">rus</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RC666-701</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">O. N. Tkacheva</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Losartan in postmenopausal women with essential arterial hypertension</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2010</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Aim. To study losartan effectiveness and safety in postmenopausal women with essential arterial hypertension (EAH), and with or without hormone replacement therapy (HRT). Material and methods. In total, 58 postmenopausal women with EAH were followed up for 6 months after being administered antihypertensive therapy (AHT) with losartan, due to inadequate blood pressure (BP) control. Group I (n=30) did not receive HRT, while Group II (n=28) was administered HRT. Losartan effects on BP dynamics, endothelium-dependent vasodilatation (EDVD), intima-media thickness (IMT) of carotid arteries (CA), lipid and carbohydrate metabolism were assessed, as well as losartan tolerability. Results. Losartan therapy resulted in target BP level achievement in both groups. At the study end, EDVD increase was statistically significant in Group I (р&lt;0,05) and highly significant in Group II (р&lt;0,001). In both groups, a tendency towards CA IMT reduction was observed. In all participants, a positive dynamics of lipid profile was observed, but it reached statistical significance only for low-density lipoprotein cholesterol in Group II. After 6 months, insulin sensitivity was normalized in all patients. The tolerability of losartan was good throughout the study period. Conclusion. In postmenopausal women with AH, adding losartan to the AHT scheme demonstrated good antihypertensive effectiveness, insulin sensitivity normalization, endothelial function and lipid profile improvement. Among women receiving AHT and HRT, antihypertensive effect, as well as beneficial effects on endothelial function and lipid profile, was greater than in women receiving AHT only.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">артериальная гипертония</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">постменопауза</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">лозартан</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Diseases of the circulatory (Cardiovascular) system</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">A. V. Barabashkina</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">I. M. Novikova</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">N. V. Sharashkina</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Кардиоваскулярная терапия и профилактика</subfield><subfield code="d">«SILICEA-POLIGRAF» LLC, 2019</subfield><subfield code="g">9(2010), 6, Seite 25-31</subfield><subfield code="w">(DE-627)1725534363</subfield><subfield code="x">26190125</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:9</subfield><subfield code="g">year:2010</subfield><subfield code="g">number:6</subfield><subfield code="g">pages:25-31</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/7583c3ea53714e26875299df90356076</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://cardiovascular.elpub.ru/jour/article/view/2141</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/1728-8800</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2619-0125</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">9</subfield><subfield code="j">2010</subfield><subfield code="e">6</subfield><subfield code="h">25-31</subfield></datafield></record></collection>
callnumber-first	R - Medicine
author	O. N. Tkacheva
spellingShingle	O. N. Tkacheva misc RC666-701 misc артериальная гипертония misc постменопауза misc лозартан misc Diseases of the circulatory (Cardiovascular) system Losartan in postmenopausal women with essential arterial hypertension
authorStr	O. N. Tkacheva
ppnlink_with_tag_str_mv	@@773@@(DE-627)1725534363
format	electronic Article
delete_txt_mv	keep
author_role	aut aut aut aut
collection	DOAJ
remote_str	true
callnumber-label	RC666-701
illustrated	Not Illustrated
issn	26190125
topic_title	RC666-701 Losartan in postmenopausal women with essential arterial hypertension артериальная гипертония постменопауза лозартан
topic	misc RC666-701 misc артериальная гипертония misc постменопауза misc лозартан misc Diseases of the circulatory (Cardiovascular) system
topic_unstemmed	misc RC666-701 misc артериальная гипертония misc постменопауза misc лозартан misc Diseases of the circulatory (Cardiovascular) system
topic_browse	misc RC666-701 misc артериальная гипертония misc постменопауза misc лозартан misc Diseases of the circulatory (Cardiovascular) system
format_facet	Elektronische Aufsätze Aufsätze Elektronische Ressource
format_main_str_mv	Text Zeitschrift/Artikel
carriertype_str_mv	cr
hierarchy_parent_title	Кардиоваскулярная терапия и профилактика
hierarchy_parent_id	1725534363
hierarchy_top_title	Кардиоваскулярная терапия и профилактика
isfreeaccess_txt	true
familylinks_str_mv	(DE-627)1725534363
title	Losartan in postmenopausal women with essential arterial hypertension
ctrlnum	(DE-627)DOAJ084683821 (DE-599)DOAJ7583c3ea53714e26875299df90356076
title_full	Losartan in postmenopausal women with essential arterial hypertension
author_sort	O. N. Tkacheva
journal	Кардиоваскулярная терапия и профилактика
journalStr	Кардиоваскулярная терапия и профилактика
callnumber-first-code	R
lang_code	rus
isOA_bool	true
recordtype	marc
publishDateSort	2010
contenttype_str_mv	txt
container_start_page	25
author_browse	O. N. Tkacheva A. V. Barabashkina I. M. Novikova N. V. Sharashkina
container_volume	9
class	RC666-701
format_se	Elektronische Aufsätze
author-letter	O. N. Tkacheva
author2-role	verfasserin
title_sort	losartan in postmenopausal women with essential arterial hypertension
callnumber	RC666-701
title_auth	Losartan in postmenopausal women with essential arterial hypertension
abstract	Aim. To study losartan effectiveness and safety in postmenopausal women with essential arterial hypertension (EAH), and with or without hormone replacement therapy (HRT). Material and methods. In total, 58 postmenopausal women with EAH were followed up for 6 months after being administered antihypertensive therapy (AHT) with losartan, due to inadequate blood pressure (BP) control. Group I (n=30) did not receive HRT, while Group II (n=28) was administered HRT. Losartan effects on BP dynamics, endothelium-dependent vasodilatation (EDVD), intima-media thickness (IMT) of carotid arteries (CA), lipid and carbohydrate metabolism were assessed, as well as losartan tolerability. Results. Losartan therapy resulted in target BP level achievement in both groups. At the study end, EDVD increase was statistically significant in Group I (р<0,05) and highly significant in Group II (р<0,001). In both groups, a tendency towards CA IMT reduction was observed. In all participants, a positive dynamics of lipid profile was observed, but it reached statistical significance only for low-density lipoprotein cholesterol in Group II. After 6 months, insulin sensitivity was normalized in all patients. The tolerability of losartan was good throughout the study period. Conclusion. In postmenopausal women with AH, adding losartan to the AHT scheme demonstrated good antihypertensive effectiveness, insulin sensitivity normalization, endothelial function and lipid profile improvement. Among women receiving AHT and HRT, antihypertensive effect, as well as beneficial effects on endothelial function and lipid profile, was greater than in women receiving AHT only.
abstractGer	Aim. To study losartan effectiveness and safety in postmenopausal women with essential arterial hypertension (EAH), and with or without hormone replacement therapy (HRT). Material and methods. In total, 58 postmenopausal women with EAH were followed up for 6 months after being administered antihypertensive therapy (AHT) with losartan, due to inadequate blood pressure (BP) control. Group I (n=30) did not receive HRT, while Group II (n=28) was administered HRT. Losartan effects on BP dynamics, endothelium-dependent vasodilatation (EDVD), intima-media thickness (IMT) of carotid arteries (CA), lipid and carbohydrate metabolism were assessed, as well as losartan tolerability. Results. Losartan therapy resulted in target BP level achievement in both groups. At the study end, EDVD increase was statistically significant in Group I (р<0,05) and highly significant in Group II (р<0,001). In both groups, a tendency towards CA IMT reduction was observed. In all participants, a positive dynamics of lipid profile was observed, but it reached statistical significance only for low-density lipoprotein cholesterol in Group II. After 6 months, insulin sensitivity was normalized in all patients. The tolerability of losartan was good throughout the study period. Conclusion. In postmenopausal women with AH, adding losartan to the AHT scheme demonstrated good antihypertensive effectiveness, insulin sensitivity normalization, endothelial function and lipid profile improvement. Among women receiving AHT and HRT, antihypertensive effect, as well as beneficial effects on endothelial function and lipid profile, was greater than in women receiving AHT only.
abstract_unstemmed	Aim. To study losartan effectiveness and safety in postmenopausal women with essential arterial hypertension (EAH), and with or without hormone replacement therapy (HRT). Material and methods. In total, 58 postmenopausal women with EAH were followed up for 6 months after being administered antihypertensive therapy (AHT) with losartan, due to inadequate blood pressure (BP) control. Group I (n=30) did not receive HRT, while Group II (n=28) was administered HRT. Losartan effects on BP dynamics, endothelium-dependent vasodilatation (EDVD), intima-media thickness (IMT) of carotid arteries (CA), lipid and carbohydrate metabolism were assessed, as well as losartan tolerability. Results. Losartan therapy resulted in target BP level achievement in both groups. At the study end, EDVD increase was statistically significant in Group I (р<0,05) and highly significant in Group II (р<0,001). In both groups, a tendency towards CA IMT reduction was observed. In all participants, a positive dynamics of lipid profile was observed, but it reached statistical significance only for low-density lipoprotein cholesterol in Group II. After 6 months, insulin sensitivity was normalized in all patients. The tolerability of losartan was good throughout the study period. Conclusion. In postmenopausal women with AH, adding losartan to the AHT scheme demonstrated good antihypertensive effectiveness, insulin sensitivity normalization, endothelial function and lipid profile improvement. Among women receiving AHT and HRT, antihypertensive effect, as well as beneficial effects on endothelial function and lipid profile, was greater than in women receiving AHT only.
collection_details	GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ SSG-OLC-PHA GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700
container_issue	6
title_short	Losartan in postmenopausal women with essential arterial hypertension
url	https://doaj.org/article/7583c3ea53714e26875299df90356076 https://cardiovascular.elpub.ru/jour/article/view/2141 https://doaj.org/toc/1728-8800 https://doaj.org/toc/2619-0125
remote_bool	true
author2	A. V. Barabashkina I. M. Novikova N. V. Sharashkina
author2Str	A. V. Barabashkina I. M. Novikova N. V. Sharashkina
ppnlink	1725534363
callnumber-subject	RC - Internal Medicine
mediatype_str_mv	c
isOA_txt	true
hochschulschrift_bool	false
callnumber-a	RC666-701
up_date	2024-07-04T00:07:06.370Z
_version_	1803604854181986304
fullrecord_marcxml	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ084683821</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230502081526.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230311s2010 xx \|\|\|\|\|o 00\| \|\|rus c</controlfield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ084683821</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJ7583c3ea53714e26875299df90356076</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">rus</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RC666-701</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">O. N. Tkacheva</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Losartan in postmenopausal women with essential arterial hypertension</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2010</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Aim. To study losartan effectiveness and safety in postmenopausal women with essential arterial hypertension (EAH), and with or without hormone replacement therapy (HRT). Material and methods. In total, 58 postmenopausal women with EAH were followed up for 6 months after being administered antihypertensive therapy (AHT) with losartan, due to inadequate blood pressure (BP) control. Group I (n=30) did not receive HRT, while Group II (n=28) was administered HRT. Losartan effects on BP dynamics, endothelium-dependent vasodilatation (EDVD), intima-media thickness (IMT) of carotid arteries (CA), lipid and carbohydrate metabolism were assessed, as well as losartan tolerability. Results. Losartan therapy resulted in target BP level achievement in both groups. At the study end, EDVD increase was statistically significant in Group I (р&lt;0,05) and highly significant in Group II (р&lt;0,001). In both groups, a tendency towards CA IMT reduction was observed. In all participants, a positive dynamics of lipid profile was observed, but it reached statistical significance only for low-density lipoprotein cholesterol in Group II. After 6 months, insulin sensitivity was normalized in all patients. The tolerability of losartan was good throughout the study period. Conclusion. In postmenopausal women with AH, adding losartan to the AHT scheme demonstrated good antihypertensive effectiveness, insulin sensitivity normalization, endothelial function and lipid profile improvement. Among women receiving AHT and HRT, antihypertensive effect, as well as beneficial effects on endothelial function and lipid profile, was greater than in women receiving AHT only.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">артериальная гипертония</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">постменопауза</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">лозартан</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Diseases of the circulatory (Cardiovascular) system</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">A. V. Barabashkina</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">I. M. Novikova</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">N. V. Sharashkina</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Кардиоваскулярная терапия и профилактика</subfield><subfield code="d">«SILICEA-POLIGRAF» LLC, 2019</subfield><subfield code="g">9(2010), 6, Seite 25-31</subfield><subfield code="w">(DE-627)1725534363</subfield><subfield code="x">26190125</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:9</subfield><subfield code="g">year:2010</subfield><subfield code="g">number:6</subfield><subfield code="g">pages:25-31</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/7583c3ea53714e26875299df90356076</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://cardiovascular.elpub.ru/jour/article/view/2141</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/1728-8800</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2619-0125</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">9</subfield><subfield code="j">2010</subfield><subfield code="e">6</subfield><subfield code="h">25-31</subfield></datafield></record></collection>
score	7.401434

Nicht das Richtige dabei?

Schreiben Sie uns!

Losartan in postmenopausal women with essential arterial hypertension

Nicht das Richtige dabei?

Zugang & Verfügbarkeit

Vorhandene Bände

Nicht das Richtige dabei?